Please login to the form below

patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is administered intravenously every few weeks.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.
Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

How early-stage clinical research is facilitating the new wave of personalised medicines

The first ever siRNA therapy was only approved by the US Food and Drug Administration (FDA) in 2018 – Patisiran for the treatment of the nerve disease (polyneuropathy) – and two further siRNA
20 for 2020 – Five pharma leaders to watch in 2020

So far, its first launch Onpattro (patisiran) has been growing pretty slowly.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Its pivotal APOLLO trial showed nearly all patisiran-treated patients saw the disease halted or slowed, with more than half seeing their neuropathy reversed.
Deal Watch table for January 2014

Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.
Pharma deals during January 2014

The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...: Highly competitive salary

Exciting Medical Writer Career Opportunity for Postdoc, Medcomms: Highly competitive salary

Add my company

We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...

Virtual Steering Committee & Peer Influence Program: In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges: The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement: How does Pharma-HCP engagement need to evolve in today's digital landscape?...

Email:
Password: